PTPRC and neoplasm: Analyses of the tumor immune infiltrates revealed no changes in immune infiltration, leukocytes (CD45+), lymphocytes (CD11b− within CD45+), TAMs (F4/80+CD11b+ within CD45+), or TANs (Ly6G+ CD11b+ within CD45+) between genotypes (Fig. 1b and Supplementary Fig. 1a, b).